Yarina, pills, 63pcs

Composition

film-coated tablets, each active tablet contains:

ethinyl estradiol 0.03 mg,

drospirenone 3.00 mg.

Indications

contraception

Contraindications

Thrombosis and thromboembolism, as well as pre-thrombosis conditions, currently or in the anamnesis, cerebrovascular disorders; migraine with focal neurological symptoms currently or in the anamnesis; diabetes mellitus with vascular complications; multiple or pronounced risk factors for venous or arterial thrombosis, including complicated lesions of the valvular heart apparatus; atrial fibrillation; diseases of the brain or coronary arteries; uncontrolled arterial hypertension; serious surgery with prolonged immobilization; smoking over the age of 35; pancreatitis with severe hypertriglyceridemia at present or in the anamnesis; liver failure and severe liver diseases (until liver tests return to normal); liver tumors (benign or malignant) at present or in the anamnesis; severe renal failure, acute renal failure; adrenal gland infection insufficiency; detected or suspected hormone-dependent malignancies (including those of the genitals or mammary glands); vaginal bleeding of unknown origin; pregnancy or suspected pregnancy; breast-feeding period; hypersensitivity to any of the components of Yarina.

Use with caution. If any of the conditions/risk factors listed below are currently present, then the potential risk and expected benefit of using combined oral contraceptives should be carefully weighed in each individual case: risk factors for thrombosis and thromboembolism; diseases that may cause peripheral circulatory disorders; hereditary angioedema; hypertriglyceridemia, liver diseases; diseases that first occurred or worsened during pregnancy or against the background of previous use of sex hormones (for example, jaundice, cholestasis, cholelithiasis, otosclerosis with hearing impairment, porphyria, herpes of pregnant women, Sydenham’s chorea); postpartum period.

Side effects

Menstrual irregularities may occur, such as irregular bleeding (spotting or bleeding), especially during the first months of use.

While taking combined oral contraceptives in women, other undesirable effects were observed, the relationship of which with the use of drugs is not confirmed, but it is not refuted.

For more information, see the instructions for use.

How to take, course of use and dosage

Pills should be taken orally in the order indicated on the package, every day at about the same time, with a small amount of water.

Take one tablet a day continuously for 21 days.

Taking the next package begins after a 7-day break in taking pills, during which withdrawal bleeding usually occurs.

If you miss taking the drug, you should follow the rules for taking missed pills.

Storage conditions

At room temperature no higher than 25 °C

Shelf life

3 years

Active ingredient

Drospirenone, Ethinyl Estradiol

Conditions of release from pharmacies

By prescription

Dosage form

Tablets

Description

For women of childbearing age, For adults as prescribed by a doctor

Indications

Contraception